Article Text

Download PDFPDF
Defining the path: lung cancer CT screening in Europe
  1. Matthew E Callister1,
  2. Sam M Janes2
  1. 1 Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  2. 2 Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
  1. Correspondence to Dr Sam M Janes, Lungs for Living Research Centre, UCL Respiratory, University College London, Rayne Building, 5 University Street, London WC1E 6JF, UK; s.janes{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since the publication of the National Lung Screening Trial (NLST) in 2011 demonstrating a 20% reduction in lung cancer-specific mortality by annual low-dose CT (LDCT),1 implementation of screening has continued apace in the USA. Other developed nations, perhaps mindful of the potential cost implications of national screening programmes, have been more reticent, with many awaiting the final outcome data from the largest European randomised trial—the Dutch-Belgian Lung Cancer Screening trial (NELSON)  study which remains in follow-up.2

Despite the convincing mortality reduction in NLST, questions remain about implementation of LDCT screening for lung cancer. Unresolved issues include how to best identify high-risk individuals for screening, what is the most appropriate screening interval to achieve an optimal balance between mortality reduction and cost-effectiveness and how to minimise possible harms associated with screening—particularly overdiagnosis. This issue of Thorax includes two papers which provide important additions to accumulating evidence in this field.

Paci and colleagues3 report lung cancer incidence and mortality rates from the Italian Lung Cancer Screening Trial (ITALUNG) randomised lung cancer screening trial conducted in Tuscany, Italy, commencing in 2004. From an invited population of over 71 232 subjects aged 55–69 years, 1613 were randomised to four rounds of annual LDCT screening and 1593 to usual care. Like many of the other European screening studies, ITALUNG was not powered to demonstrate mortality reduction in isolation, and pooled analysis with other similarly designed randomised trials is planned.

As expected, lung cancer incidence was higher in the intervention group during the 4-year screening period (55% excess diagnoses vs usual care group). However, this was followed by a compensatory reduction in diagnoses during the 5-year follow-up period, such that there was no significant difference in incidence rates between the groups at the end of the study. After a median follow-up of 9 years, the authors report …

View Full Text


  • Contributors Both the authors contributed equally to this work.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Lung cancer
    Eugenio Paci Donella Puliti Andrea Lopes Pegna Laura Carrozzi Giulia Picozzi Fabio Falaschi Francesco Pistelli Ferruccio Aquilini Cristina Ocello Marco Zappa Francesca M Carozzi Mario Mascalchi and the ITALUNG Working Group Eugenio Paci Donella Puliti Marco Zappa Cristina Ocello Gianfranco Manneschi Carmen Visioli Giovanna Cordopatri Francesco Giusti Ida Esposito Andrea Lopes Pegna Roberto Bianchi Cristina Ronchi Laura Carrozzi Ferruccio Aquilini Stella Cini Mariella De Santis Francesco Pistelli Filomena Baliva Antonio Chella Laura Tavanti Michela Grazzini Florio Innocenti Ilaria Natali Mario Mascalchi Maurizio Bartolucci Elena Crisci Agostino De Francisci Massimo Falchini Silvia Gabbrielli Giuliana Roselli Andrea Masi Fabio Falaschi Luigi Battola Annalisa De Liperi Cheti Spinelli Letizia Vannucchi Alessia Petruzzelli Davide Gadda Anna Talina Neri Franco Niccolai Luca Vaggelli Alessandra Vella Francesca Maria Carozzi Cristina Maddau Simonetta Bisanzi Giulia Picozzi Alberto Janni Alfredo Mussi Marco Lucchi Camilla Comin Gabriella Fontanini Adele Renza Tognetti Laura Iacuzio Adele Caldarella Alessandro Barchielli Carlo Alberto Goldoni
  • Lung cancer
    Uraujh Yousaf-Khan Carlijn van der Aalst Pim A de Jong Marjolein Heuvelmans Ernst Scholten Joan Walter Kristiaan Nackaerts Harry Groen Rozemarijn Vliegenthart Kevin ten Haaf Matthijs Oudkerk Harry de Koning